All Patents Lead to Ralph Baric

Moderna, NIAID, and Ralph Baric's Role in mRNA Vaccine Development

Synopsis

The timeline unfolds, interweaving collaborations between Moderna, NIAID, and Ralph Baric. The journey commences in 2015 with Baric's chimeric virus creation in tandem with Wuhan Institute of Virology, while Moderna and NIAID join forces to tackle coronaviruses. The plot thickens in 2016 with Moderna's patent filing, containing a genetic sequence found later in the SARS-CoV-2 furin cleavage site. A Material Transfer Agreement in 2019 allows the exchange of mRNA candidates, and by 2020, human trials for mRNA-1273 commence, propelled by financial success for Moderna's CEO. Questions arise about the 2016 patent's connection to SARS-CoV-2, creating a complex narrative reflecting the multifaceted origins and collaborations shaping the success of mRNA vaccines during the COVID-19 pandemic.

Unraveling the Timeline

Highlights the chronological events, collaborations, and questions surrounding the development of mRNA vaccines, specifically Moderna's mRNA-1273, with a focus on the 2016 pa…